2020/08/07
Breast cancer is the most common cancer among women in Taiwan, but limited by technology, when women have abnormalities in ultrasound and X-rays, they can only find out whether they have cancer through biopsy. Peking University has developed blood breast cancer detection technology, hoping to help Breast cancer screening.
On the 6th, Taipei Medical University and the National Institutes of Health held a matchmaking meeting for R&D achievements, releasing 14 technologies together, focusing on the four major technical highlights of cancer treatment, precision medicine, microbial flora, and biomedical materials engineering. Among them, Ruo-Kai Lin, an associate professor at Beijing Medical University, developed the Precise Blood Breast Cancer Detection Technology, which is helpful for early detection of breast cancer.
Ruo-Kai Lin said that the current clinical breast cancer screening is limited by the difficulty of accurate judgment by imaging. When women find abnormalities in ultrasound and chest Xray examinations, they must do invasive biopsy to confirm whether they have cancer. However, clinically, as many as 70% of abnormalities detected by ultrasound or X-ray and received biopsy are actually benign, and there is no need for biopsy or treatment at all, as long as continuous follow-up is enough. Therefore, in order to break the limitations of breast cancer screening, Ruo-Kai Lin invested in blood test research, hoping that this technology can accurately report, so that doctors can determine whether patients should continue to follow up or need to do biopsy. Ruo-Kai Lin pointed out that the research of this technology took nearly 5 years. It was to do microarray analysis from the genomes of breast cancer patients in Taiwan, analyze the variation of their genomes, and use the degree of abnormal free methylated DNA in the patients plasma to distinguish patients from healthy people. The higher the degree, the higher the chance of developing cancer.
Precise blood breast cancer detection technology can be applied to early breast cancer screening, breast cancer treatment effectiveness monitoring, and recurrence prediction and tracking system to provide reference for breast cancer clinical treatment Not only can the report be issued within 5 hours, but the sensitivity is as high as 92.3%. Sexuality reached 91.7%. Ruo-Kai Lin said that in the future, extended research will also be done, such as detecting whether the cancer cells in the body have been cleared up or whether the cancer cells have recurred in the patient.